Advanced Biomed Inc. has received a notice from Nasdaq indicating that the company's common stock has failed to meet the minimum bid price requirement of $1.00 per share for the past 32 consecutive business days. This notice, however, does not immediately affect the stock's listing or trading on the Nasdaq Capital Market, where it continues to trade under the symbol "ADVB." To comply with Nasdaq's Listing Rule 5550(a)(2), Advanced Biomed has until January 14, 2026, to raise its stock price to at least $1.00 for ten consecutive business days. If compliance is not achieved by this deadline, the company may qualify for an additional 180-day extension to meet listing standards, contingent on specific conditions. Advanced Biomed is actively exploring options to address this issue within the allotted timeframe.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。